Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04684758
Other study ID # ANRS 14058
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 14, 2021
Est. completion date June 30, 2022

Study information

Verified date July 2022
Source ANRS, Emerging Infectious Diseases
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In France, men who have sex with men (MSM) born abroad are the most affected population by HIV, in terms of HIV incidence and prevalence of undiagnosed infections. Close to 50% of born-abroad HIV-infected MSM are living in the region of Ile-de-France, which is the metropolitan area of Paris. Recent European data, not including France, suggest that born-abroad MSM have the highest rate of post-migration HIV acquisition. Many vulnerability factors could explain le burden of HIV in this group of the population. A better understanding of vulnerability factors related to post-migration HIV acquisition should allow to improve HIV prevention and screening strategies among born-abroad MSM living in France. This, in turn, should reduce the burden of HIV in this population in France.


Description:

A better understanding of vulnerability factors related to post-migration HIV acquisition should allow to improve HIV prevention and screening strategies among born-abroad MSM living in France. This, in turn, should reduce the burden of HIV in this population in France. Multicenter, cross-sectional, two-year study in the region Ile-de-France. The study is based on the self-completion of a questionnaire, built after an exploratory qualitative study. Constitution of a representative sample of born-abroad HIV-infected MSM from patients followed up for HIV in Paris area. Questionnaires will collect data needed to estimate the post-migration HIV acquisition rates, and will explore contextual and individual factors leading to high exposure to HIV. The participants will complete a questionnaire translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service. A brief eCRF will collect clinical and biological data, and historical viral sequences in associated virology departments, when available.


Recruitment information / eligibility

Status Completed
Enrollment 1048
Est. completion date June 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Cis-gender men who report having sex with men; - Over 18 years of age; - Type 1 HIV infected; - Born in a country other than France and arrived in France at the age of 15 at the earliest; - Followed in Ile-de-France for their HIV infection and having consulted at least once in the participating center during the last 12 months; - Non-opposition to the collection of their health data, after being well informed of the study and the patient rights in accordance with RGPD and LIL (French regulation) Exclusion Criteria: - Somatic or psychiatric pathology making it impossible to participate in an investigation; - Communication disorder making it impossible to read (or oral responses in the event of assisted questionnaire completion).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Self-completion of a questionnaire
The questionnaire will be translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service, if necessary.

Locations

Country Name City State
France Hôpital Pitié-Salpêtrière, AP-HP, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLESP), INSERM 1136 Paris

Sponsors (2)

Lead Sponsor Collaborator
ANRS, Emerging Infectious Diseases Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Phylogenetic analysis in participants having acquired HIV before and after the migration, between them and with other populations Comparing the viral sequence from participant samples, will allow to estimate the proportion of viral sequences included in viral clusters comprising viral sequences from patients born in France and born outside France (proportion of participants, n (%)) Through study completion, an average of 12 months
Other Motivations and migratory processes Analyses of participant questionnaires, will identify the motivations and the migratory processes in the global context of the country of origin (proportion of participants per item, based on responses to questionnaire, n (%)) Through study completion, an average of 12 months
Other Vulnerability factors To determine the vulnerability factors for HIV infection, including social inequalities in health, in the country of origin, during the migration, and in France (proportion of participants per item, based on responses to questionnaire, n (%)) Through study completion, an average of 12 months
Other Health contacts Description of health contacts, if any, with health system before HIV diagnosis (proportion of participants per item, based on responses to questionnaire (%)) Through study completion, an average of 12 months
Other Missed opportunities of pre-exposure prophylaxis Description of missed opportunities of pre-exposure prophylaxis access (proportion of participants per item, based on responses to questionnaire, n (%)) Through study completion, an average of 12 months
Other HIV healthcare Description of HIV care, including antiretroviral treatment and viral suppression coverage (proportion of participants, n (%)) Through study completion, an average of 12 months
Primary Post-migration proportion of HIV acquisition in born-abroad HIV-positive MSM living in Ile-de-France Estimation of the post-migration proportion of HIV acquisition in born-abroad HIV-positive MSM living in Ile-de-France (proportion of participants, n (%)) Through study completion, an average of 12 months
Secondary Timing of HIV infection for people infected in France Estimation of the timing of HIV infection for people infected in France (years, median, IQR) Through study completion, an average of 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05362916 - Letermovir in ART-treated HIV-infected Persons N/A
Recruiting NCT05085145 - Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV Phase 4
Recruiting NCT05123144 - A Hybrid Type II Trial of the Optimizing Resilience and Coping With HIV Through Internet Delivery in Ryan White Clinics in Chicago Phase 2